Anlotinib for Hepatocellular Carcinoma

People's Hospital of Guangxi Zhuang Autonomous Region200 enrolled

Overview

The purpose of this study is to observe and explore the effect of single or combined treatment of arotinib on the survival and prognosis of patients with advanced liver cancer in the real world, and to summarize the treatment experience of a wide range of people.

Study Type

OBSERVATIONAL

Enrollment

200

Conditions

Liver Neoplasms

Interventions

AnlotinibDRUG

This is an observational study

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: 1. Age: ≥ 18 years old, male or female; 2. Patients with advanced liver cancer were diagnosed; 3. Patients assessed by doctors to benefit from single or combined treatment of arotinib; 4. Patients volunteered to join the project. Exclusion Criteria: None

Locations (1)

People's Hospital of Guangxi Zhuang Autonomous Region

Nanning, Guangxi, China

RECRUITING

Outcomes

Primary Outcomes

Overall Survival

Time frame: From date of admission until the date of death from any cause, assessed up to 24 months

Secondary Outcomes

PFS

Progression Free Survival

Time frame: From date of admission until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.